Circulating DNA for treatment and follow-up in squamous cell cancers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031154

Enrollment

600

Registered

2023-02-22

Start date

2023-07-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

squamous cell cancers C80

Interventions

Group 1: prospective observational clinical study At defined time points before, during and after completion of therapy, ctDNA will be measured from the blood of the patient. The aim is to investiga

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histopathologically verified SCC Eligible for curatively or palliatively intended treatment = 18 of years Written and oral consent

Exclusion criteria

Exclusion criteria: Other cancer disease within 5 year of SCC diagnosis Conditions that will contraindicate blood samples Potential lack of compliance to standard FU program and study participation.

Design outcomes

Primary

Measure	Time frame
The primary objective is to investigate the clinical utility of circulating DNA assessments over the course of treatment and follow-up, by analyzing the correlation of the cfDNA (quantitative and molecular characteristics) to clinical outcome parameters including prognosis, elimination patterns and recurrence. The analysis of ctDNA is performed from the blood of the patient. Blood samples are taken before starting therapy, during therapy and several times during follow-up. Depending on the treatment strategy, up to 10 samples are planned.	—

Measure

Time frame

The primary objective is to investigate the clinical utility of circulating DNA assessments over the course of treatment and follow-up, by analyzing the correlation of the cfDNA (quantitative and molecular characteristics) to clinical outcome parameters including prognosis, elimination patterns and recurrence. The analysis of ctDNA is performed from the blood of the patient. Blood samples are taken before starting therapy, during therapy and several times during follow-up. Depending on the treatment strategy, up to 10 samples are planned.

—

Secondary

Measure	Time frame
Secondary objectives are to compare different methods for measuring circulating DNA in SCCs.	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026